Skip to main content

DDX17 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion.

Be the first to review this product! Submit a review

Images

Western blot - Human DDX17 knockout HEK-293 cell lysate (AB261660), expandable thumbnail
  • Western blot - Human DDX17 knockout HEK-293 cell lysate (AB261660), expandable thumbnail
  • Western blot - Human DDX17 knockout HEK-293 cell lysate (AB261660), expandable thumbnail

Key facts

Cell type
HEK-293
Species or organism
Human
Tissue
Kidney
Knockout validation
Next Generation Sequencing, Western blot
Mutation description
Knockout achieved by CRISPR/Cas9 X = 1 bp insertion

Alternative names

What's included?

1 Kit
Components
Human DDX17 knockout HEK293 cell lysate
1 x 100 µg
Human wild-type HEK-293 cell lysate
1 x 100 µg

Recommended products

DDX17 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion.

Key facts

Cell type
HEK-293
Mutation description
Knockout achieved by CRISPR/Cas9 X = 1 bp insertion
Concentration
Loading...

Properties

Gene name
DDX17
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Next Generation Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Storage

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Notes

Knockout cell lysate achieved by CRISPR/Cas9.

Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

DDX17 also known as RNA helicase p72 is an enzyme that unwinds RNA molecules. It belongs to the DEAD-box protein family. Its mechanical action involves utilizing ATP to unwind RNA facilitating various RNA processing events. DDX17 weighs approximately 73 kDa making it a relatively large protein. The enzyme expresses in multiple tissues but shows substantial activity in HEK 293 cells a human embryonic kidney cell line.

Biological function summary

This enzyme plays a significant role in RNA metabolism. DDX17 is part of the spliceosome complex which is essential for splicing pre-mRNA into mature mRNA. Through its helicase activity DDX17 ensures the proper remodeling of RNA structures which is necessary for accurate splicing. The protein also contributes to the regulation of gene expression and has been observed to influence transcription factors.

Pathways

RNA processing and maturation are key biological functions of DDX17. The protein integrates into the mRNA splicing pathway where it orchestrates proper RNA folding and splice site selection. Furthermore DDX17 interacts with other DEAD-box proteins such as DDX5 to assist in chromatin remodeling and transcription regulation facilitating efficient gene expression.

Associated diseases and disorders

Abnormal DDX17 expression or mutation links to certain cancers including breast cancer and leukemia. The protein along with DDX5 affects tumor progression by regulating pathways involved in cell proliferation. These pathways and protein interactions highlight the importance of DDX17 in maintaining normal cell function and its potential as a therapeutic target in cancer treatment.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com